"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.
Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.
The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.
A generally healthy, young adult male presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.
The review is an update to a drug safety communication initially issued in 2010 after trial results suggested a possible increased risk for prostate cancer with use of entacapone.
The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.
The agency said the gene therapy should remain on the market while it assesses the situation and does not impact their evaluation of data from the human clinical trials.
The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?
Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.
A 27-year-old man has had right arm numbness for about 2 weeks. What’s in your differential?
For years, study participants had been suffering with migraine symptoms and had failed at least three to five therapies before enrolling in the trial.
Although Alzheimer disease is not infectious by any common definition of the term, research over the past 20 years has confirmed long-standing speculation that the molecular mechanism driving neurodegeneration is fundamentally the same in Alzheimer disease and the prototypical infectious proteopathy—prion disease.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.